Identification and Prevention: Underutilized Tools in Diabetes Treatment?

Stephen A. Brunton, MD, FAAFP

In recent years, we have seen significant progress in the area of diabetes management. The importance of applying innovative approaches tailored to the specific needs and characteristics of patients, using technology such as mobile smartphones and “apps” to make the process more convenient and patient-friendly and focusing on analytics and outcomes to establish the best path

to improving patient health, has been recognized. Although the disease continues to do harm at an alarming rate and there remains much work to be done, the importance of implementing new ways to educate and assist patients has been acknowledged.

However, efforts to find improved methods to help patients manage their diabetes may have overshadowed an equally important element:

identifying those with or at significant risk of developing the disease who are unaware of their condition. According to the Centers for Disease Control and Prevention, roughly 7 million of the 26 million people affected by diabetes in the United States fall into this category.¹

Numerous factors contribute to this troubling statistic. However, as a lifelong primary care physician

Clinical Diabetes

Editor

David F. Kruger, MSN,
APN-BC, BC-ADM

Deputy Editors

Virginia Valentine, CNS,
BC-ADM, CDE
John R. White, Jr., PA-C,
PharmD

Associate Editors

Arti Bhan, MD
John E. Brunner, MD
Stephen Brunton, MD
Robert J. Chilton, MD
Joseph Largay, PAC, CDE
Gayle M. Lorenzi, RN, CDE
Melinda Downie Maryniuk,
Med, RD, CDE, FADA
Heather Remtema, MPH, RD,
CCRP

Editorial Board

Leslie Barrett, MS, RD, CDE
Nisha Basu, MD, MPH
Christine Beebe, MS
Nathaniel G. Clark, MD,
MS, RD
Kelly Close, BA, MBA
Nancy J. D'Hondt, RPh,
CDE, FADE
Ruth P. Hertzman-Miller,
MD, MPH
Debbie Hinnen, ARNP,
BC-ADM, CDE, FAAN,
FAADE
Jenna Johnson, MS, BC-FNP,
BC-ADM, CDE
Brian Lake, DO
Catherine L. Martin, MS,
RN, BC-ADM, CDE
Lucia M. Novak, MSN,
ANP-BC, BC-ADM
Kyle Peters, PharmD,
BC-ADM, CDE
Thomas Repas, DO, FACP,
FACOI, FNLA, FACE, CDE
Terry Ridge, DNP, ANP-BC,
BC-ADM, CRCC
Joanne Rinker, MS, RD,
CDE, LDN
Melissa Roman, MSN,
FNP-BC, BC-ADM
Mansur E. Shomali, MD, CM
Neil Skolnik, MD
Condit F. Steil, PharmD,
CDE, FAPhA
Curtis Triplitt, PharmD, CDE
Patti Urbanski, Med, RD,
LD, CDE

**Managing Director,
Scholarly Journals**
Christian S. Kohler

Director, Scholarly Journals
Heather Norton

**Manager, Periodicals
Production**
Keang Hok

Managing Editor
Debbie Kendall

**Vice President, Membership
& Direct Response Marketing**
Richard Erb

**Vice President, Corporate
Alliances**
Nancy Stinson Harris

Advertising Manager
Julie DeVoss Graff

**Associate Director,
Billing & Collections**
Laurie Ann Hall

American Diabetes
Association Officers

Chair of the Board
Dwight Holing

**President, Health Care
& Education**
Marjorie Cypress, PhD, RN,
CNP, CDE

President, Medicine & Science
Elizabeth R. Seaquist, MD

Secretary/Treasurer
Robert J. Singley, MBA

Chair of the Board-Elect
Janel L. Wright, JD

**President-Elect, Health Care
& Education**
David G. Marrero, PhD

**President-Elect, Medicine
& Science**
Samuel Dagogo-Jack, MD,
FRCP

Secretary/Treasurer-Elect
Richard Farber, MBA

Vice Chair of the Board
Robin J. Richardson

**Vice President, Health
Care & Education**
Margaret Powers, PhD,
RD, CDE

**Vice President, Medicine
& Science**
Desmond Schatz, MD

Vice Secretary/Treasurer
Lorrie Welker Liang

Chief Executive Officer
Larry Hausner, MBA

Clinical Diabetes

A PUBLICATION OF THE AMERICAN DIABETES ASSOCIATION®, INC.™

Clinical Diabetes Mission Statement

The mission of *Clinical Diabetes* is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. *Clinical Diabetes* is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.

ADA Mission Statement

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

Clinical Diabetes (Print ISSN 0891-8929, Online ISSN 1945-4953) is published every January, April, July, and October by the American Diabetes Association®, Inc., 1701 N. Beauregard St., Alexandria, VA 22311. For subscription information, call toll free (800) 232-3472, 8:30 a.m. to 5:00 p.m. EST, Monday through Friday. Outside the U.S., call (703) 549-1500.

Claims for missing issues must be made within 6 months of publication. The publisher expects to supply missing issues free of charge only when losses have been sustained in transit and when the reserve stock permits.

Postmaster: Send change of address to *Clinical Diabetes* COA, 1701 N. Beauregard St., Alexandria, VA 22311-1733.

©American Diabetes Association®, Inc., 2014.
Printed in the USA.

Opinions expressed in signed articles are those of the authors and are not necessarily endorsed by the American Diabetes Association.

Advertising Representatives

Consumer Northeast/Southeast/West
Nancy Greenwald, Vice President, Advertising Sales
& Custom Media, TMG Custom Media,
ngreenwald@adamediasales.com, (646) 783-3786

Consumer Midwest
Lauren Loomis, lloomis@adamediasales.com;
TMG Custom Media, (920) 839-1186

Pharmaceutical

B. Joseph Jackson, joejackson@jacksongaeta.com;
Paul Nalbandian, paulnalbandian@jacksongaeta.com;
Tina Auletta, jggtina@aol.com; Jackson Gaeta Group,
(973) 403-7677

(PCP), I can speak to three directly: misconceptions about the clinical appropriateness of screenings that can identify a patient's condition, lack of access to these types of screenings, and failure to appreciate the impact screening results can have on patient behavior and health. Unfortunately, these factors do not adequately account for the long-term cost of not taking preventive health measures, much less the long-term health of patients.

From a clinical perspective, screening for diabetes is a no-brainer. As a disease that significantly affects quality of life, with acceptable methods of treatment, an asymptomatic period during which timely treatment can improve outcomes, cost-effective tests, and a high incidence level, diabetes meets all of the long-accepted criteria for determining whether screening is appropriate.² This is to say nothing of the other diseases that can be identified or addressed through basic screenings that test for multiple chronic conditions.

Five diseases cause more than two-thirds of all U.S. deaths annually: heart disease, cancer, stroke, chronic obstructive pulmonary disease (bronchitis, emphysema), and diabetes. Chronic diseases such as these also account for ~ 75% of the nation's spending.³ Yet, they are also among the most preventable through early detection and screening.

Lack of access is another challenge to identifying patients with diabetes or prediabetes through screenings. As a family physician, I am acutely aware of the growing shortage of PCPs in this country, which is likely to worsen as millions of new patients enter the health care system under the Affordable Care

Act. There is also the cost issue; not all insurance plans cover screening for chronic diseases such as diabetes.

However, as with diabetes management, new and innovative ways for people to receive diabetes screenings have been emerging. Community-based screenings are one example of how individuals are finding nontraditional solutions to take a preventive approach to their health. These convenient and affordable screenings are offered directly to consumers (often in partnership with local hospitals) and are ideal for patients who may not regularly visit a PCP.

Case in point: in 2012, Life Line Screening, the largest community screenings provider in the United States, screened almost 150,000 people for diabetes. They found almost 26,000 cases of prediabetes, 7,200 cases of diabetes, and nearly 250 cases of critical findings that required urgent and potentially life-saving attention. These figures underscore the important role screenings can play in helping people more actively assess and address their health, which ultimately benefits not only patients but the health care system as a whole.

There is also significant evidence demonstrating that screening results, communicated in the right way, can change the behavior and lifestyle of patients—a particularly valuable outcome for those with prediabetes.⁴ Recent research presented at the 2012 American College of Cardiology meeting revealed that providing an image of a diseased artery helped patients improve adherence to therapies (statins and weight loss) for other chronic diseases that drive improved patient outcomes and can be viewed

as equivalents of diabetes.⁵ As any health care provider who has treated patients with diabetes knows, the ability to meaningfully motivate people to take their health into their own hands can be essential, and screening results can help drive this impact.

To continue making progress against diabetes, the medical community must recognize the importance of not just treating evident disease, but also adopting a preventive mindset. Otherwise, we are likely to see the millions of undiagnosed and avoidable cases of the disease increase. And that is an outcome none of us can afford.

REFERENCES

¹Centers for Disease Control and Prevention: Number of Americans with diabetes rises to nearly 26 million [press release, 26 January 2011]. Available from http://www.cdc.gov/media/releases/2011/p0126_diabetes.html. Accessed 12 October 2013

²Frame PS, Carlson SJ: A critical review of periodic health screening using specific screening criteria. *J Fam Pract* 2:283–289, 1975

³Centers for Disease Control and Prevention: Chronic diseases: the power to prevent, the call to control: at a glance 2009. Available from <http://www.cdc.gov/chronicdisease/resources/publications/aag/chronic.htm>. Accessed 12 October 2013

⁴Markowitz SM, Park ER, Delahanty LM, O'Brien KE, Grant RW: Perceived impact of diabetes genetic risk testing among patients at high phenotypic risk for type 2 diabetes. *Diabetes Care* 34:568–573, 2011

⁵Studies: CAC scoring, imaging of arteries is a wake-up call. *Medical Device Daily* 28 March 2012, p. 1, 7

Stephen A. Brunton, MD, FAAFP, is executive vice president for education at the Primary Care Education Consortium in Charlotte, N.C. He is also an associate editor of Clinical Diabetes.

Note of disclosure: Dr. Brunton serves as a consultant to Life Line Screening.

CONGRATULATIONS TO THE RECIPIENTS OF THE 2013 PATHWAY TO STOP DIABETES® RESEARCH AWARDS

**PATHWAY
TO STOP DIABETES**

American Diabetes Association.
RESEARCH FOUNDATION

DIABETES.ORG/PATHWAY

Joshua Thaler, MD, PhD at the University of Washington, in Seattle, Wa., received a *Accelerator Award* for his basic research project entitled, "Modulating Glial-Neuronal Interactions to Treat Obesity And Diabetes"

Kathleen Page, MD at the University of Southern California, in Los Angeles, Ca., received a *Accelerator Award* for her translational research project entitled, "Neural Mechanisms in Maternal-Fetal Programming for Obesity and Diabetes"

Wolfgang Peti, PhD at Brown University School of Medicine and the Miriam Hospital in Providence, R.I., received an *Accelerator New to Diabetes Award* for his project entitled, "Novel, Innovative Insights into Insulin Signaling and Regulation using NMR Spectroscopy"

Michael Dennis, PhD at Pennsylvania State University, in University Park, Pa., received an *Initiator Award* for his basic research project entitled, "Hyperglycemia-Induced Translational Control of Gene Expression in the Retina"

Stephen Parker, PhD at the National Human Genome Research Institute in Bethesda, Md., received an *Initiator Award* for his basic research project entitled, "Deconstructing Type 2 Diabetes Using Genome-Wide High-Density Multi-Tissue 'Omics' Profiling"

**WE'RE NOT INVESTING IN RESEARCH.
WE'RE INVESTING IN RESEARCHERS.**

History shows that great breakthroughs often come from unexpected places. The only constant is talent. Pathway to Stop Diabetes® provides five- to seven-year grants of \$1.625 million to enlist a new generation of brilliant scientists in the field of diabetes research, regardless of their current field of study. Now in its second year, Pathway provides the freedom, autonomy, professional mentoring and collaborative opportunities that will drive progress. It's a radical new road for research. One that can accelerate your career and transform the future of diabetes.

**PATHWAY
TO STOP DIABETES**

American Diabetes Association.
RESEARCH FOUNDATION

APPLICATIONS BY
NOMINATION ONLY.
DEADLINE: JULY 1, 2014.
FIND OUT MORE AT
DIABETES.ORG/PATHWAY